Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Decreases By 18.0%

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) was the target of a large decline in short interest in April. As of April 15th, there was short interest totaling 244,306 shares, a decline of 18.0% from the March 31st total of 297,898 shares. Based on an average daily trading volume, of 55,070 shares, the short-interest ratio is presently 4.4 days. Approximately 4.3% of the shares of the stock are sold short.

Analyst Ratings Changes

ARMP has been the subject of a number of research reports. HC Wainwright lifted their target price on shares of Armata Pharmaceuticals from $9.00 to $15.00 and gave the stock a “buy” rating in a research report on Monday, February 23rd. JonesTrading began coverage on shares of Armata Pharmaceuticals in a research report on Monday, January 5th. They issued a “buy” rating and a $15.00 price target on the stock. Two research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Armata Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $15.00.

Institutional Trading of Armata Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in ARMP. Geode Capital Management LLC grew its holdings in Armata Pharmaceuticals by 5.1% in the 4th quarter. Geode Capital Management LLC now owns 109,888 shares of the company’s stock valued at $690,000 after buying an additional 5,342 shares during the period. SeaCrest Wealth Management LLC lifted its holdings in shares of Armata Pharmaceuticals by 17.3% during the 4th quarter. SeaCrest Wealth Management LLC now owns 40,988 shares of the company’s stock worth $274,000 after acquiring an additional 6,034 shares during the period. State Street Corp boosted its position in shares of Armata Pharmaceuticals by 26.1% in the fourth quarter. State Street Corp now owns 50,800 shares of the company’s stock worth $319,000 after acquiring an additional 10,500 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Armata Pharmaceuticals in the fourth quarter worth approximately $108,000. Finally, Millennium Management LLC purchased a new stake in Armata Pharmaceuticals in the fourth quarter valued at approximately $164,000. 3.57% of the stock is owned by institutional investors and hedge funds.

Armata Pharmaceuticals Stock Performance

NYSEAMERICAN ARMP traded down $1.09 during mid-day trading on Friday, reaching $8.89. 56,696 shares of the stock were exchanged, compared to its average volume of 68,916. The stock has a market capitalization of $326.17 million, a PE ratio of -1.84 and a beta of 1.31. Armata Pharmaceuticals has a 1-year low of $1.17 and a 1-year high of $16.34. The business’s fifty day simple moving average is $10.72 and its 200 day simple moving average is $7.84.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last issued its quarterly earnings results on Wednesday, March 25th. The company reported ($3.42) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($3.23). The business had revenue of $1.09 million during the quarter, compared to the consensus estimate of $0.74 million.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.